目的 研究多烯磷脂酰膽堿聯(lián)合復(fù)方丹參滴丸對(duì)非酒精性脂肪肝患者的臨床治療效果。方法 選擇2012年1月-2015年12月在西安醫(yī)學(xué)院附屬寶雞醫(yī)院進(jìn)行診治的非酒精性脂肪肝患者116例，隨機(jī)分為觀察組與對(duì)照組，每組58例。對(duì)照組采用復(fù)方丹參滴丸治療，觀察組采用多烯磷脂酰膽堿聯(lián)合復(fù)方丹參滴丸治療，均治療3個(gè)月。比較兩組的臨床有效率；分別于治療前后檢測(cè)肝功能指標(biāo)：天氨酸氨基轉(zhuǎn)移酶（AST）、丙氨酸氨基轉(zhuǎn)移酶（ALT）、γ-谷氨酰轉(zhuǎn)肽酶（γ-GT）、總膽汁酸（TBIL）；血脂指標(biāo)：總膽固醇（TC）、三酰甘油（TG）；肝纖維化指標(biāo)：層粘連蛋白（LN）、透明質(zhì)酸（HA）、Ⅲ型前膠原（PCⅢ）、IV型膠原（IV-C）；并進(jìn)行上腹部CT平掃，計(jì)算肝/脾CT比值。結(jié)果 觀察組的有效率為91.4%（53/58），明顯高于對(duì)照組的72.4%（42/58）（P<0.05）；與同組治療前比較，治療后兩組的AST、ALT、γ-GT、TBIL、TC、TG水平均明顯降低，肝/脾CT比值明顯升高（P<0.05），且觀察組的改善程度明顯優(yōu)于對(duì)照組（P<0.05）；與治療前比較，兩組治療后的LN、PCⅢ、IV-C和HA水平均明顯降低（P<0.05），且觀察組的降低程度明顯優(yōu)于對(duì)照組（P<0.05）。結(jié)論 多烯磷脂酰膽堿聯(lián)合復(fù)方丹參滴丸可以明顯改善非酒精性脂肪肝患者的肝功能和肝纖維化，降低血脂。

Objective To investigate the clinical effect of Compound Danshen Dripping Pill (CDCP) combined with polyene phosphatidyl choline in the treatment of nonalcoholic fatty liver disease. Methods Patients with nonalcoholic fatty liver disease (116 cases) treated in Xi'an Medical University Affiliated Baoji Hospital from January 2012 to December 2015 were selected and divided into two groups randomly. Control group was treated with CDDP, and observation group was treated with CDDP combined with polyene phosphatidyl choline, the two groups were treated for 3 months. The clinical efficiency of two groups was compared. The following indicators were detected before and after treatment respectively, such as liver function indicators:aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyltransferase (γ-GT) and total bile acid (TBIL); blood lipid indicators:total cholesterol (TC), triacylglycerol (TG); and liver triglyceride fibrosis indicators:laminin (LN), hyaluronic acid (HA), procollagen Ⅲ (PC Ⅲ), and type IV collagen (IV-C), and carried on the upper abdomen CT plain scan, the liver/spleen CT ratio were calculated. Results After treatment, the effective rate of the observation group was 91.4% (53/58), significantly higher than that of the control group 72.4% (42/58) (P<0.05). After treatment, the levels of AST, ALT, γ-GT, TBIL, TC and TG in two groups were decreased significantly compared with the same group before treatment and lower in the observation group (P<0.05), and liver/spleen CT ratio was increased significantly and higher in the observation group (P<0.05). After treatment, the levels of LN, PC Ⅲ, IV-C and HA in two groups were decreased significantly compared with the same group before treatment and lower in the observation group (P<0.05). Conclusion CDDP combined with polyene phosphatidyl choline can significantly improve the liver function and liver fibrosis in patients with nonalcoholic fatty liver disease, and lower blood lipid, which has high clinical value.